指南与共识放疗物理与技术姑息放疗与转移瘤

MR-Linac患者的同行评审小组共识流程是否影响临床诊疗?影响与可行性评估

Does a peer review group consensus process for MR-Linac patients affect clinical care? Evaluation of impact and feasibility.
指南 / 共识 · Clin Transl Radiat Oncol · 2024-07-03

本研究前瞻性收集两家中心2023年6月8日至9月21日每周MR-Linac同行评审会议讨论的55例病例,依据澳大利亚和新西兰放射学家皇家学院(RANZCR)开发的放射肿瘤学同行评审审核工具(PRAT)分析计划变更率与程度。同行评审导致36.4%(n=20)的治疗计划发生变更,其中3.6%(n=2)为需推迟治疗的重大变更;作者推荐尽可能对所有MRgRT病例进行同行评审。

要点

  • 同行评审导致36.4%(n=20)的治疗计划变更,3.6%(n=2)为需推迟治疗的重大变更。
  • 最常见变更为危及器官(OAR)体积(勾画及增加OAR保护)16.4%(n=9)、总剂量和分次10.9%(n=6)。
  • SBRT计划、寡转移/寡进展部位及再照射病例的变更率较高。

核心结论

  • 较高的计划变更率支持同行评审在MRgRT中的价值。
  • 作者推荐尽可能对所有MRgRT病例进行同行评审,尤其是涉及SBRT计划、寡转移/寡进展部位和/或再照射的病例。

研究设计与样本

  • 前瞻性收集两家中心2023年6月8日至9月21日每周MR-Linac同行评审会议讨论的55例病例。
  • 依据澳大利亚和新西兰放射学家皇家学院(RANZCR)开发的放射肿瘤学同行评审审核工具(PRAT)分析计划变更率和程度。

主要发现

  • 同行评审导致36.4%(n=20)的治疗计划变更,其中3.6%(n=2)为需推迟治疗的重大变更。
  • 最常见变更为危及器官(OAR)体积涉及勾画和增加OAR保护,占16.4%(n=9)。
  • 总剂量和分次变更占10.9%(n=6),靶区剂量覆盖变更占5.5%(n=3)。
  • SBRT计划患者变更率为39.1%对比22.2%,寡转移/寡进展部位为38.1%对比30.7%,再照射病例为41.2%对比34.2%。
  • 病例讨论平均用时7分钟(范围2-15分钟)。

临床怎么用

  • 作者推荐尽可能对所有MRgRT病例进行同行评审,尤其是涉及SBRT计划、寡转移/寡进展部位和/或再照射的病例。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Peer review is an important component of quality assurance in radiotherapy. To our knowledge, there are no studies reporting on the feasibility and outcomes of the peer review process for magnetic resonance (MR) guided radiotherapy (MRgRT) on the MR linear accelerator (MR-Linac) despite the planning complexity involved and its evolving clinical indications. This study aimed to quantify the rate of change in treatment plans post-peer review and the time and resources required. MATERIALS AND METHODS: Fifty-five cases presented at weekly MR-Linac peer review meetings across two centres from 8 June to 21 September 2023 were prospectively collected. Cases were analysed to determine the rate and extent of plan changes based on the Peer Review Audit Tool for radiation oncology (PRAT) developed by the Royal Australian and New Zealand College of Radiologists (RANZCR). RESULTS: Peer review resulted in changes to 36.4 % of treatment plans (n = 20), with 3.6 % (n = 2) having major changes requiring deferment of treatment. The most frequent changes were to organs at risk (OAR) volumes involving both delineation and increased OAR sparing (16.4 %, n = 9), total dose and fractionation (10.9 %, n = 6) and target volume dose coverage (5.5 %, n = 3). Patients with SBRT plans (39.1 % cf 22.2 %), oligometastatic/oligoprogressive sites (38.1 % cf 30.7 %) and reirradiation cases (41.2 % cf 34.2 %) had higher rates of change. Cases took a mean of 7 min (range 2-15 minutes) to discuss. CONCLUSION: The high rates of plan changes support the value of peer review in MRgRT. We recommend, where possible that all MRgRT cases, particularly those involving SBRT plans, oligometastatic/oligoprogressive sites, and/or reirradiation, be subject to peer review.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Sin Y, Batumalai V, de Leon J, et al. Does a peer review group consensus process for MR-Linac patients affect clinical care? Evaluation of impact and feasibility. Clin Transl Radiat Oncol. 2024. PMID: 39130107. doi:10.1016/j.ctro.2024.100816

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。